FDA Downgrades SMA Newborn Test to Class II
Published Date: 6/11/2026
Rule
Summary
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
SMA Newborn Test Reclassified to Class II
The FDA classified the Spinal Muscular Atrophy (SMA) newborn screening test system as Class II (special controls), with the order effective June 11, 2026 and applicable since November 9, 2022. The agency says this classification provides reasonable assurance of safety and will enhance patients' access to the test.
Detailed Special-Control Study and Labeling Rules
To qualify under Class II, device makers must meet specified special controls, including extensive design verification and validation (detailed device description, analytical and clinical studies with summaries and 95% confidence intervals), multi-site reproducibility, lot-to-lot filter paper studies, reagent and shipping stability studies, software descriptions, and specific labeling statements (including that the test is prescription-only and presumptive positives require confirmatory diagnostic testing).
Lower Regulatory Hurdles for Test Makers
FDA says placing the SMA newborn screening test into Class II via the De Novo process reduces regulatory burdens and allows the device to serve as a predicate for future devices, which can speed market access for similar tests.
510(k) Premarket Submission Still Required
The order states that Spinal Muscular Atrophy newborn screening test systems are subject to premarket notification under section 510(k) of the FD&C Act at this time because FDA has not determined they should be exempt under section 510(m).
Prescription Screening; Positives Need Confirmation
The SMA newborn screening test system is identified as a prescription in vitro diagnostic intended to detect SMN1 gene deletions from dried blood spot specimens, and presumptive positive results are intended to be followed up by diagnostic confirmatory testing.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-11739, Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
Next: 2026-11747, Safety Zones; Annual Events in the Captain of the Port Eastern Great Lakes Zone
The Coast Guard is setting up safety zones on the water for fun annual events in the Eastern Great Lakes this July 2026. Boat operators must follow rules and listen to Coast Guard directions during these times to keep everyone safe. These temporary zones might delay some boaters but won’t cost extra money.